Tyra Biosciences, Inc. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Tyra Biosciences completed a $400M underwritten public offering in September 2026 (led by RA Capital Management) and reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC: 79% overall response rate and 64% complete response rate at 60 mg QD (n=14), with 100% ORR and 75% CR among single-lesion patients (n=8); no Grade 3 treatment-related adverse events at this dose. Cash position is now $700.5M as of September 30, 2026, funding operations through 2030. Q3 2026 net loss was $51.1M vs. $29.9M in Q3 2025; R&D expenses increased 69% YoY to $43.1M.
Why this rating
Financing of $400M is 135% of market cap; strong early clinical efficacy data with favorable safety supports Phase 3 pathway. Material near-term catalyst, but company remains pre-approval with execution risk.
Tradability signal
NO TRADE
No trade: positive news with only -2.4% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.40% over 4 hrs, n=417). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $22.18 | +10 min · unknown $21.81 ▼ 1.65% | +30 min · unknown $22.49 ▲ 1.42% | +1 hr · unknown $21.54 ▼ 2.86% | +4 hrs · unknown $20.88 ▼ 5.84% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.